25814-07-7

Usage

Uses

Used in Pharmaceutical Industry:
(4-Amino-3-chloro-phenyl)-acetic acid ethyl ester is used as a key intermediate in the synthesis of various drugs. Its unique chemical structure allows it to be a versatile building block for the development of new medications for a wide range of conditions.
Used in Organic Chemistry:
(4-AMino-3-chloro-phenyl)-acetic acid ethyl ester is also used as a starting material for the preparation of other organic compounds. Its reactivity and functional groups make it a valuable component in the synthesis of various chemical products.
Safety Precautions:
It is important to handle and store (4-Amino-3-chloro-phenyl)-acetic acid ethyl ester with caution, following proper safety protocols and regulations to ensure the safety of individuals and the environment.

Upstream product

• 1093222-12-8 ethyl 3-chloro-4-nitrophenylacetate 
• 5438-70-0 ethyl (4-amino-3,5-dibromophenyl)acetate 

Downstream Products

• 945561-64-8 ethyl (3-chloro-4-{1,3-dioxo-4,9-bis[(phenylmethyl)oxy]-1,3-dihydro-2H-benzo[f]isoindol-2-yl}phenyl)acetate 
• 1093222-14-0 ethyl 3-chloro-4-[N'-(4-fluoro-2-methylphenyl)ureido]phenylacetate 
• 1093222-13-9 ethyl 3-chloro-4-[N'-(3-fluoro-2-methylphenyl)ureido]phenylacetate 
• 1093222-15-1 ethyl 3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetate 
• 1198420-17-5 ethyl {3-chloro-4-[({2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetate 
• 1198420-12-0 ethyl {3-chloro-4-[({5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetate 
• 1198420-19-7 ethyl (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetate 
• 1198420-07-3 ethyl (3-chloro-4-{[(5-chloro-2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetate 
• 1198420-24-4 ethyl (3-chloro-4-{[(5-chloro-2-{[(2-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetate 
• 22106-57-6 (4-amino-3-chlorophenyl)acetic acid 
• 1021167-92-9 ethyl {4-[4,9-bis(ethyloxy)-1,3-dioxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]-3-chlorophenyl}acetate 
• 1198420-20-0 (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid 
• 1198420-25-5 (3-chloro-4-{[(5-chloro-2-{[(2-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid 
• 1198420-08-4 GSK₂₅₃A 

Relevant academic research and scientific papers

Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin

As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3- methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I > Br > Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with Ki (ant) = 2.77 and 2.19 nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6′-iodononivamide.

3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES

This invention relates to novel indazole derivatives of formula I: wherein R1 to R7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can

NOVEL EP4 RECEPTOR AGONIST COMPOUNDS

A compound selected from the group consisting of: (3-chloro-4-{[(5-chloro-2-{[(2- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; {3-chloro-4-[({5-chloro-2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-{[(5-chloro-2-{[(3- chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(5-chloro-2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}-2- fluorophenyl)acetic acid; {3-chloro-4-[({2-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (3-chloro-4-{[(2-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({2-chloro-6-[(phenylmethyl)oxy]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(2-chloro-6-{[(3-chlorophenyl)methyl]oxy}phenyl)carbonyl]amino}phenyl)acetic acid; {4-[({5-chloro-2-[(phenylmethyl)amino]phenyl}carbonyl)amino]phenyl}acetic acid; (4-{[(5-chloro-2-{[(3-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid; and (4-{[(5-chloro-2-{[(2-chlorophenyl)methyl]amino}phenyl)carbonyl]amino}phenyl)acetic acid, or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

BENZO [F] ISOINDOLES AS EP4 RECEPTOR AGONISTS

The present invention relates to naphthalene derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

NOVEL ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4 and R5, X and Y are as defined in the specification; a process for preparing such compounds; a ph

NAPHTHALENE DERIVATIVES USED AS EP4 RECEPTOR AGONISTS

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1 R2 R3, X and Y are as defined in the specification; a process fo preparing such compounds; a pharmaceutical composition comprising

BENZAMIDE DERIVATIVES AS EP4 RECEPTOR AGONISTS

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, R4, R5, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist

Optimization of benzoic acid derivatives by introducing substituents into the diphenyl urea moiety led to the identification of compound 20l as a potent VLA-4 antagonist. Compound 20l inhibited eosinophil infiltration into bronchial alveolar lavage fluid

ISOINDOL DERIVATIVES AS EP4 RECEPTOR AGONISTS

The present invention relates to indole derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.

BENZOISOINDOLE DERIVATIVES FOR THE TREATMENT OF PAIN

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R1, R2, R3, X and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprisi